Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amoxicillin + clarithromycin + pantoprazole is a triple therapy combination used primarily to treat peptic ulcer disease caused by Helicobacter pylori infection. Each component has a specific role in the treatment: - **Amoxicillin**: A bactericidal antibiotic that prevents the formation of bacterial cell walls necessary for survival - **Clarithromycin**: A bacteriostatic antibiotic that inhibits protein synthesis required for bacterial growth - **Pantoprazole**: A proton pump inhibitor that blocks the gastric proton pump enzyme, reducing stomach acid production This combination therapy typically achieves H. pylori eradication rates of 93-94% when administered for 7-14 days. It helps heal duodenal ulcers and gastritis while preventing recurrence by eliminating the underlying bacterial infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + clarithromycin + pantoprazole.